ESMO 16th World Congress on GI Cancer

pancreatic cancer

Adding Novel Agent to Standard Therapy Improves Survival in Patients With Pancreatic Cancer After Prior Gemcitabine-Based Therapy

The addition of the novel agent MM-398 to standard treatment improved overall survival in patients with metastatic pancreatic cancer who have already received gemcitabine, according to a phase III tri...

colorectal cancer

Second-Line Regorafenib Improves Survival in Metastatic Colorectal Cancer

In the phase III double-blind, placebo-controlled ­CONCUR trial,1 previously treated patients with stage IV adenocarcinoma of the colon or rectum had increased overall survival, the primary endpoint, ...

colorectal cancer

Phase III Trial Shows Improved Survival With TAS‑102 in Metastatic Colorectal Cancer Refractory to Standard Therapies

The new combination agent TAS-102 can improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers reported at the ESMO ...

Advertisement

Advertisement



Advertisement